You are using an outdated browser. Please upgrade your browser to improve your experience.

empagliflozin

Empagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Target Activities